Copy Link Print Information

GSK-872

110 Cited Publications
Customer Review

Based on 110 publication(s) in Google Scholar

GSK-872 is a RIPK3 inhibitor, which binds RIP3 kinase domain with an IC50 of 1.8 nM, and inhibits kinase activity with an IC50 of 1.3 nM. GSK-872 decreases the RIPK3-mediated necroptosis and subsequent cytoplasmic translocation and expression of HMGB1, as well as ameliorates brain edema and neurological deficits in early brain injury.

For research use only. We do not sell to patients.

  • Purity: 99.55%
  • CAS No.: 1346546-69-7
  • Formula: C19H17N3O2S2
  • Molecular Weight:383.49
  • Storage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • GSK-872 Chemical Structure
    GSK-872 Chemical Structure
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
  • Experimental Validation Results for GSK-872
CAS No.: 1346546-69-7
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of GSK-872:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) GSK-872

More
Customer Validation & Images
WBCell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • Cell Proliferation/Viability Assay
  • WB
  • WB
  • WB
  • WB

All RIP kinase Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • GSK-872 Chemical Structure
    GSK-872 Chemical Structure
    1/16
  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 8;16(1):4288. [Abstract]

    Customer Validation
     Viability of L929 cells with RIPK3 knockout (RIPK3-/-) and overexpressed RIPK3 K51A, treated with GSK'872 with (open triangle) and without (open circle) zVAD. The results showed that GSK'872, at low micromolar concentrations (e.g., 1.6 μM), significantly reduces the viability of cells expressing the ATPase-inactive RIPK3 K51A mutant.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 8;16(1):4288. [Abstract]

    Customer Validation
     GSK-872 (10 µM; 5 h) enhances the interaction between RIPK3 and RIPK1 in L929 cells.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 8;16(1):4288. [Abstract]

    Customer Validation
     GSK-872 (10 µM; 5 h) enhances the interaction between RIPK3 and RIPK1 in L929 cells , thereby activating the apoptotic pathway and leading to the cleavage of caspase 8 and caspase 3.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Mar;33(3):201-214. [Abstract]

    Customer Validation
     GSK-872 (1-10 μM) significantly inhibits MLKL phosphorylation and IL-1β P17 releas in SARS-CoV-2 (48 h)-infected Calu-3 cells.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2022 Apr;24(4):471-482. [Abstract]

    Customer Validation
     Flag-mRIP3 WT or mutants (K51A, D161N or RHIMMut) were expressed in RIP3-deficient L929 cells and treated as indicated (DMSO, 5 μM GSK-872 or 20 μM zVAD). Cell viability was measured, and data are represented as means ± s.d. of biological triplicates.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Transl Stroke Res. 2021 Dec;12(6):991-1017. [Abstract]

    Customer Validation
     Delayed administration of GSK-872 reduces the protein level of RIP3K or MLKL and GFAP after OGD/Re injury. Astrocytes are exposed to OGD for 6 h followed by reoxygenation for 24 h. GSK-872 (10 μM) is added to the cells upon reoxygenation.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 Oct 9;5(1):235. [Abstract]

    Customer Validation
     Calu-3 cells pretreated with GSK-872 (5 μM) or NSA (2.5 μM) were infected with SARS-CoV-2 (MOI = 0.1) for 48 h. P17 levels in the supernatants and intracellular levels of MLKL, pMLKL, and pro-IL-1β were determined by western blotting. The results showed that GSK-872 inhibited pMLKL in the infected cells.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: J Immunol. 2018 Apr 15;200(8):2826-2834. [Abstract]

    Customer Validation
     Wild-type BMDMs are treated with or without PM (20 μg/ml), and DMSO, Necrostatin-1 (10 μM), and GSK’872 (5 μM) as indicated, the expression of p-IkBα and p-RELA are measured by Western blot.

  • 1/16

    GSK-872 purchased from MedChemExpress. Usage Cited in: Chin J of Oncol Prev and Treat. 2018, 10(2): 105-109.

    Customer Validation
     In the inhibitor group，GSK'872 is injected intrathecally at 30 min before model establishment; in the saline group，the same volume of saline is intrathecally injected.

  • GSK-872